Revive Therapeutics Ltd. is focused on advancing novel treatments for rare diseases.
Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2016
Revive Completes $1,500,000 Non-Brokered Private Placement
Revive Therapeutics Ltd. Announces US FDA Acceptance of IND of Bucillamine for the Treatment of Cystinuria
Revive Therapeutics Announces New CEO and New President
Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria